Lil­ly, in­sulin users end $13.5M set­tle­ment plan fol­low­ing fed­er­al judge's de­ci­sion

A set­tle­ment be­tween Eli Lil­ly and in­sulin users has col­lapsed af­ter a fed­er­al judge’s rul­ing that de­nied class cer­ti­fi­ca­tion for the law­suit.

The orig­i­nal set­tle­ment stemmed from a 2017 law­suit in which pa­tients sued the three biggest in­sulin man­u­fac­tur­ers — Eli Lil­ly, No­vo Nordisk and Sanofi — and ac­cused them of “ar­ti­fi­cial and fraud­u­lent in­fla­tion” of their in­sulin prices in the US.

Last May, Lil­ly and the plain­tiffs an­nounced a deal in which Lil­ly would pay $13.5 mil­lion and con­tin­ue to cap out-of-pock­et in­sulin costs at $35 per month for the next four years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER